1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Japan Orphan Drugs Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 Japan Orphan Drugs Market Landscape
5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)
6 Japan Orphan Drugs Market - Breakup by Drug Type
6.1 Biological
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2018-2023)
6.1.3 Market Forecast (2024-2032)
6.2 Non-Biological
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2018-2023)
6.2.3 Market Forecast (2024-2032)
7 Japan Orphan Drugs Market - Breakup by Disease Type
7.1 Oncology
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2018-2023)
7.1.3 Market Forecast (2024-2032)
7.2 Hematology
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2018-2023)
7.2.3 Market Forecast (2024-2032)
7.3 Neurology
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2018-2023)
7.3.3 Market Forecast (2024-2032)
7.4 Cardiovascular
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2018-2023)
7.4.3 Market Forecast (2024-2032)
7.5 Others
7.5.1 Historical and Current Market Trends (2018-2023)
7.5.2 Market Forecast (2024-2032)
8 Japan Orphan Drugs Market - Breakup by Phase
8.1 Phase I
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2018-2023)
8.1.3 Market Forecast (2024-2032)
8.2 Phase II
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2018-2023)
8.2.3 Market Forecast (2024-2032)
8.3 Phase III
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2018-2023)
8.3.3 Market Forecast (2024-2032)
8.4 Phase IV
8.4.1 Overview
8.4.2 Historical and Current Market Trends (2018-2023)
8.4.3 Market Forecast (2024-2032)
9 Japan Orphan Drugs Market - Breakup by Top Selling Drugs
9.1 Revlimid
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2018-2023)
9.1.3 Market Forecast (2024-2032)
9.2 Rituxan
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2018-2023)
9.2.3 Market Forecast (2024-2032)
9.3 Copaxone
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2018-2023)
9.3.3 Market Forecast (2024-2032)
9.4 Opdivo
9.4.1 Overview
9.4.2 Historical and Current Market Trends (2018-2023)
9.4.3 Market Forecast (2024-2032)
9.5 Keytruda
9.5.1 Overview
9.5.2 Historical and Current Market Trends (2018-2023)
9.5.3 Market Forecast (2024-2032)
9.6 Imbruvica
9.6.1 Overview
9.6.2 Historical and Current Market Trends (2018-2023)
9.6.3 Market Forecast (2024-2032)
9.7 Avonex
9.7.1 Overview
9.7.2 Historical and Current Market Trends (2018-2023)
9.7.3 Market Forecast (2024-2032)
9.8 Sensipar
9.8.1 Overview
9.8.2 Historical and Current Market Trends (2018-2023)
9.8.3 Market Forecast (2024-2032)
9.9 Soliris
9.9.1 Overview
9.9.2 Historical and Current Market Trends (2018-2023)
9.9.3 Market Forecast (2024-2032)
9.10 Others
9.10.1 Historical and Current Market Trends (2018-2023)
9.10.2 Market Forecast (2024-2032)
10 Japan Orphan Drugs Market - Breakup by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Historical and Current Market Trends (2018-2023)
10.1.3 Market Forecast (2024-2032)
10.2 Retail Pharmacies
10.2.1 Overview
10.2.2 Historical and Current Market Trends (2018-2023)
10.2.3 Market Forecast (2024-2032)
10.3 Online Stores
10.3.1 Overview
10.3.2 Historical and Current Market Trends (2018-2023)
10.3.3 Market Forecast (2024-2032)
10.4 Others
10.4.1 Historical and Current Market Trends (2018-2023)
10.4.2 Market Forecast (2024-2032)
11 Japan Orphan Drugs Market – Breakup by Region
11.1 Kanto Region
11.1.1 Overview
11.1.2 Historical and Current Market Trends (2018-2023)
11.1.3 Market Breakup by Drug Type
11.1.4 Market Breakup by Disease Type
11.1.5 Market Breakup by Phase
11.1.6 Market Breakup by Top Selling Drugs
11.1.7 Market Breakup by Distribution Channel
11.1.8 Key Players
11.1.9 Market Forecast (2024-2032)
11.2 Kansai/Kinki Region
11.2.1 Overview
11.2.2 Historical and Current Market Trends (2018-2023)
11.2.3 Market Breakup by Drug Type
11.2.4 Market Breakup by Disease Type
11.2.5 Market Breakup by Phase
11.2.6 Market Breakup by Top Selling Drugs
11.2.7 Market Breakup by Distribution Channel
11.2.8 Key Players
11.2.9 Market Forecast (2024-2032)
11.3 Central/ Chubu Region
11.3.1 Overview
11.3.2 Historical and Current Market Trends (2018-2023)
11.3.3 Market Breakup by Drug Type
11.3.4 Market Breakup by Disease Type
11.3.5 Market Breakup by Phase
11.3.6 Market Breakup by Top Selling Drugs
11.3.7 Market Breakup by Distribution Channel
11.3.8 Key Players
11.3.9 Market Forecast (2024-2032)
11.4 Kyushu-Okinawa Region
11.4.1 Overview
11.4.2 Historical and Current Market Trends (2018-2023)
11.4.3 Market Breakup by Drug Type
11.4.4 Market Breakup by Disease Type
11.4.5 Market Breakup by Phase
11.4.6 Market Breakup by Top Selling Drugs
11.4.7 Market Breakup by Distribution Channel
11.4.8 Key Players
11.4.9 Market Forecast (2024-2032)
11.5 Tohoku Region
11.5.1 Overview
11.5.2 Historical and Current Market Trends (2018-2023)
11.5.3 Market Breakup by Drug Type
11.5.4 Market Breakup by Disease Type
11.5.5 Market Breakup by Phase
11.5.6 Market Breakup by Top Selling Drugs
11.5.7 Market Breakup by Distribution Channel
11.5.8 Key Players
11.5.9 Market Forecast (2024-2032)
11.6 Chugoku Region
11.6.1 Overview
11.6.2 Historical and Current Market Trends (2018-2023)
11.6.3 Market Breakup by Drug Type
11.6.4 Market Breakup by Disease Type
11.6.5 Market Breakup by Phase
11.6.6 Market Breakup by Top Selling Drugs
11.6.7 Market Breakup by Distribution Channel
11.6.8 Key Players
11.6.9 Market Forecast (2024-2032)
11.7 Hokkaido Region
11.7.1 Overview
11.7.2 Historical and Current Market Trends (2018-2023)
11.7.3 Market Breakup by Drug Type
11.7.4 Market Breakup by Disease Type
11.7.5 Market Breakup by Phase
11.7.6 Market Breakup by Top Selling Drugs
11.7.7 Market Breakup by Distribution Channel
11.7.8 Key Players
11.7.9 Market Forecast (2024-2032)
11.8 Shikoku Region
11.8.1 Overview
11.8.2 Historical and Current Market Trends (2018-2023)
11.8.3 Market Breakup by Drug Type
11.8.4 Market Breakup by Disease Type
11.8.5 Market Breakup by Phase
11.8.6 Market Breakup by Top Selling Drugs
11.8.7 Market Breakup by Distribution Channel
11.8.8 Key Players
11.8.9 Market Forecast (2024-2032)
12 Japan Orphan Drugs Market – Competitive Landscape
12.1 Overview
12.2 Market Structure
12.3 Market Player Positioning
12.4 Top Winning Strategies
12.5 Competitive Dashboard
12.6 Company Evaluation Quadrant
13 Profiles of Key Players
13.1 Company A
13.1.1 Business Overview
13.1.2 Product Portfolio
13.1.3 Business Strategies
13.1.4 SWOT Analysis
13.1.5 Major News and Events
13.2 Company B
13.2.1 Business Overview
13.2.2 Product Portfolio
13.2.3 Business Strategies
13.2.4 SWOT Analysis
13.2.5 Major News and Events
13.3 Company C
13.3.1 Business Overview
13.3.2 Product Portfolio
13.3.3 Business Strategies
13.3.4 SWOT Analysis
13.3.5 Major News and Events
13.4 Company D
13.4.1 Business Overview
13.4.2 Product Portfolio
13.4.3 Business Strategies
13.4.4 SWOT Analysis
13.4.5 Major News and Events
13.5 Company E
13.5.1 Business Overview
13.5.2 Product Portfolio
13.5.3 Business Strategies
13.5.4 SWOT Analysis
13.5.5 Major News and Events
Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.
14 Japan Orphan Drugs Market - Industry Analysis
14.1 Drivers, Restraints, and Opportunities
14.1.1 Overview
14.1.2 Drivers
14.1.3 Restraints
14.1.4 Opportunities
14.2 Porters Five Forces Analysis
14.2.1 Overview
14.2.2 Bargaining Power of Buyers
14.2.3 Bargaining Power of Suppliers
14.2.4 Degree of Competition
14.2.5 Threat of New Entrants
14.2.6 Threat of Substitutes
14.3 Value Chain Analysis
15 Appendix